FDAnews
www.fdanews.com/articles/170793-perseons-microthermx-gains-expanded-fda-indication

Perseon's MicroThermX Gains Expanded FDA Indication

April 14, 2015

Perseon Corp.’s MicroThermX microwave ablation system has received an expanded FDA indication for procedures requiring partial or complete ablation of nonresectable liver tumors, the Salt Lake City, Utah, devicemaker announced Tuesday.

The device features Synchronous Wave Alignment technology delivering precision-guided microwave energy to cancerous soft tissue. The MicroThermX was launched in 2010 for soft tissue ablation and received an FDA indication for laparoscopic ablation procedures using image guidance earlier this month.

Formerly BSD Medical, Perseon markets cancer treatment products in the U.S., Europe and Asia. — Jason Scott